Clinical Trials Logo

Clinical Trial Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. Previous non-randomized interventions have shown that oral peppermint may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention. Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in healthy individuals.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05071833
Study type Interventional
Source University of Central Lancashire
Contact Jonathan Sinclair, PhD
Phone +447875651533
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date January 1, 2022
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04511325 - Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus N/A
Recruiting NCT04801745 - Vegan Diet, Amla Fruits and Uric Acid N/A
Not yet recruiting NCT04784624 - Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Recruiting NCT04776629 - A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Phase 2
Enrolling by invitation NCT05079529 - Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Phase 2
Recruiting NCT04802044 - COVID-19, Aging, and Cardiometabolic Risk Factors Study
Recruiting NCT02322073 - Inflammation and Obesity-associated Disease